Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Interstitial Pneumonia with Autoimmune Features (IPAF)
ChiCTR-IPR-17010813Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pirfenidone in Interstitial Pneumonia With Autoimmune Features (IPAF) and interstitial lung disease (ILD) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Lung function, High-resolution chest CT and 5 more. Started Mar 2017; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
Interstitial Pneumonia With Autoimmune Features (IPAF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR-IPR-17010813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010813.